Related references
Note: Only part of the references are listed.Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
Matteo Santoni et al.
CLINICAL GENITOURINARY CANCER (2022)
FAK in Cancer: From Mechanisms to Therapeutic Strategies
Hsiang-Hao Chuang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant melanoma
Greta Del Mistro et al.
CELL DEATH & DISEASE (2022)
Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment
Marina Roy-Luzarraga et al.
CANCER RESEARCH (2022)
IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time
Benedikt Hoeh et al.
SEMINARS IN ONCOLOGY (2022)
FAK displacement from focal adhesions: a promising strategy to target processes implicated in cancer progression and metastasis
Ioanna Antoniades et al.
CELL COMMUNICATION AND SIGNALING (2021)
Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
T. Powles
ANNALS OF ONCOLOGY (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Paradoxical activation of c-Src as a drug-resistant mechanism
Makio Higuchi et al.
CELL REPORTS (2021)
Biomarkers for renal cell tumours
Philip Zeuschner et al.
AKTUELLE UROLOGIE (2021)
Targeting FAK in anticancer combination therapies
John C. Dawson et al.
NATURE REVIEWS CANCER (2021)
mTORC2-AKT signaling to ATP-citrate lyase drives brown adipogenesis and de novo lipogenesis
C. Martinez Calejman et al.
NATURE COMMUNICATIONS (2020)
Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
Xing Huang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Genomic profiling in renal cell carcinoma
Nazli Dizman et al.
NATURE REVIEWS NEPHROLOGY (2020)
Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma
Liping Shan et al.
FRONTIERS IN ONCOLOGY (2020)
Epidemiology of Renal Cell Carcinoma
Umberto Capitanio et al.
EUROPEAN UROLOGY (2019)
von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME
Lucas Tedesco et al.
CELL DEATH & DISEASE (2019)
Clonal architectures predict clinical outcome in clear cell renal cell carcinoma
Yi Huang et al.
NATURE COMMUNICATIONS (2019)
C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas
Paulina Marona et al.
CELLS (2019)
Targeting Tyrosine kinases in Renal Cell Carcinoma: New Bullets against Old Guys
Teresa Alonso-Gordoa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors
Arpita Desai et al.
FUTURE ONCOLOGY (2019)
Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases
Chi Zhang et al.
ONCOGENE (2019)
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
Daniel J. George et al.
ONCOLOGIST (2019)
Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis
Henriett Butz et al.
ONCOTARGET (2018)
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K. Choueiri et al.
EUROPEAN JOURNAL OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy
Solene-Florence Kammerer-Jacquet et al.
TARGETED ONCOLOGY (2017)
Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling
Thomas Simon et al.
TRENDS IN MOLECULAR MEDICINE (2017)
Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review
Jung Han Kim et al.
ONCOTARGET (2017)
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
Remi Adelaiye-Ogala et al.
CANCER RESEARCH (2017)
MET/HGF pathway activation as a paradigm of resistance to targeted therapies
Brian Ko et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
L. Zhou et al.
ONCOGENE (2016)
Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
Le Qu et al.
CANCER CELL (2016)
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer
Johannes Schoedel et al.
EUROPEAN UROLOGY (2016)
Choosing the right cell line for renal cell cancer research
Klaudia K. Brodaczewska et al.
MOLECULAR CANCER (2016)
CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation
Dan-Dan Wang et al.
MOLECULAR CANCER THERAPEUTICS (2016)
MET Inhibition in Clear Cell Renal Cell Carcinoma
Zuoquan Xie et al.
JOURNAL OF CANCER (2016)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2015)
FAK signaling in human cancer as a target for therapeutics
Brian Y. Lee et al.
PHARMACOLOGY & THERAPEUTICS (2015)
The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma
Steven N. Steinway et al.
PLOS ONE (2015)
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
Kristy J. Gotink et al.
CELLULAR ONCOLOGY (2015)
Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy
B. Kim et al.
ONCOGENE (2015)
Dose-Response Analysis Using R
Christian Ritz et al.
PLOS ONE (2015)
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al.
NATURE GENETICS (2014)
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Erinn B. Rankin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Role of cMET in the Development and Progression of Colorectal Cancer
Juan Carlos Samame Perez-Vargas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
The VHL/HIF axis in clear cell renal carcinoma
Chuan Shen et al.
SEMINARS IN CANCER BIOLOGY (2013)
The paradox of Akt-mTOR interactions
Lakshmipathi Vadlakonda et al.
FRONTIERS IN ONCOLOGY (2013)
Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma
Alain Ravaud et al.
CANCER TREATMENT REVIEWS (2012)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
MET: a promising anticancer therapeutic target
Solange Peters et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma
A. Ravaud et al.
ANNALS OF ONCOLOGY (2010)
Receptor Tyrosine Kinase Coactivation Networks in Cancer
Alexander M. Xu et al.
CANCER RESEARCH (2010)
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
Virna Cepero et al.
CANCER RESEARCH (2010)
VHL and HIF signalling in renal cell carcinogenesis
Marcella M. Baldewijns et al.
JOURNAL OF PATHOLOGY (2010)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells
Stephen Hiscox et al.
CLINICAL & EXPERIMENTAL METASTASIS (2007)
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα but not S6K1
David A. Guertin et al.
DEVELOPMENTAL CELL (2006)
SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity
Estela Jacinto et al.
CELL (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion
SY Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma
N Nakaigawa et al.
CANCER RESEARCH (2006)
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells
J Halder et al.
CLINICAL CANCER RESEARCH (2005)
Expression of Axl in lung adenocarcinoma and correlation with tumor progression
YS Shieh et al.
NEOPLASIA (2005)
Share Paper
